{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:33:55Z","timestamp":1788453235306,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007914","name":"The University of Texas Southwestern Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcf.2026.05.009","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:22:42Z","timestamp":1779135762000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Changes in metabolic and pulmonary outcomes after discontinuation of glucagon-like-peptide-1 receptor agonist therapy in people with cystic fibrosis"],"prefix":"10.1016","author":[{"given":"Akruti","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7281-4797","authenticated-orcid":false,"given":"Andrew","family":"Horvit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0391-7207","authenticated-orcid":false,"given":"Jessica","family":"Abramowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5996-0661","authenticated-orcid":false,"given":"Marconi","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9829-7556","authenticated-orcid":false,"given":"Katie","family":"Kaput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6429-2479","authenticated-orcid":false,"given":"Amber","family":"Neece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5833-3532","authenticated-orcid":false,"given":"James D.","family":"Finklea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-7374","authenticated-orcid":false,"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4251-5737","authenticated-orcid":false,"given":"Sasan","family":"Mirfakhraee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jcf.2026.05.009_bib0001","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2337\/dc25-0044","article-title":"Trends in cystic fibrosis-related diabetes epidemiology between 2003 and 2018 from the U.S. cystic fibrosis foundation patient registry","volume":"48","author":"Kohler","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.009_bib0002","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ccm.2015.11.009","article-title":"Nutritional issues in cystic fibrosis","volume":"37","author":"Solomon","year":"2016","journal-title":"Clin Chest Med"},{"issue":"6","key":"10.1016\/j.jcf.2026.05.009_bib0003","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/0884533613507086","article-title":"Malnutrition in cystic fibrosis: a review","volume":"28","author":"Culhane","year":"2013","journal-title":"Nutr Clin Pract"},{"issue":"4","key":"10.1016\/j.jcf.2026.05.009_bib0004","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3945\/ajcn.112.051409","article-title":"Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study","volume":"97","author":"Stephenson","year":"2013","journal-title":"Am J Clin Nutr"},{"issue":"18","key":"10.1016\/j.jcf.2026.05.009_bib0005","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.3390\/nu16183103","article-title":"Is obesity a problem in new cystic fibrosis treatments?","volume":"16","author":"Solis-Garcia","year":"2024","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.009_bib0006","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jcf.2024.09.022","article-title":"Development of metabolic syndrome in people with Cystic Fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Ratti","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.009_bib0007","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.jcf.2026.05.009_bib0008","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/dme.14121","article-title":"Loss of incretin effect contributes to postprandial hyperglycaemia in cystic fibrosis-related diabetes","volume":"36","author":"Frost","year":"2019","journal-title":"Diabet Med"},{"issue":"4","key":"10.1016\/j.jcf.2026.05.009_bib0009","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jcf.2019.01.010","article-title":"Incretin dysfunction and hyperglycemia in cystic fibrosis: role of acyl-ghrelin","volume":"18","author":"Sun","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.009_bib0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jcf.2024.08.005","article-title":"Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis","volume":"24","author":"Park","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.05.009_bib0011","article-title":"Impact of glucagon-like-peptide-1 receptor agonist therapy on pulmonary function in people with cystic fibrosis who achieve normal body mass index","author":"Horvit","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2026.05.009_bib0012","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.jcf.2026.05.009_bib0013","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.clnu.2019.12.029","article-title":"Overweight, obesity and significant weight gain in adult patients with cystic fibrosis association with lung function and cardiometabolic risk factors","volume":"39","author":"Bonhoure","year":"2020","journal-title":"Clin Nutr"},{"issue":"7","key":"10.1016\/j.jcf.2026.05.009_bib0014","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc10-2289","article-title":"Hyperglycemia and death in cystic fibrosis-related diabetes","volume":"34","author":"Adler","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcf.2026.05.009_bib0015","article-title":"Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: a cases series and literature review","volume":"38","author":"Ahmed","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.jcf.2026.05.009_bib0016","article-title":"Letter to the editor: semaglutide-associated recurrent distal intestinal obstruction in cystic fibrosis","author":"Kamoua","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.009_bib0017","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1111\/dom.70579","article-title":"Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist","volume":"28","author":"Van Laren","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.009_bib0018","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized Controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jcf.2026.05.009_bib0019","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.jcf.2026.05.009_bib0020","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jcf.2026.05.009_bib0021","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.3390\/jcm14113791","article-title":"Weight regain after liraglutide, semaglutide or tirzepatide interruption: a narrative review of Randomized studies","volume":"14","author":"Quarenghi","year":"2025","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.009_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0740","article-title":"Association of body mass index with clinical outcomes in patients with Cystic fibrosis: a systematic review and meta-analysis","volume":"5","author":"Nagy","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.009_bib0023","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1513\/AnnalsATS.202212-1026OC","article-title":"Effects of weight change and weight cycling on lung function in overweight and obese adults","volume":"21","author":"De Soomer","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2026.05.009_bib0024","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1038\/srep08931","article-title":"The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes","volume":"5","author":"Mulrennan","year":"2015","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.009_bib0025","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jcf.2019.12.016","article-title":"Glycemic control and FEV(1) recovery during pulmonary exacerbations in pediatric cystic fibrosis-related diabetes","volume":"19","author":"Okoniewski","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2026.05.009_bib0026","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1651-2227.1994.tb13156.x","article-title":"Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections","volume":"83","author":"Lanng","year":"1994","journal-title":"Acta Paediatr"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.009_bib0027","article-title":"Positive impact of insulin treatment on clinical trend in cystic fibrosis patients: a retrospective study","volume":"93","author":"Giugno","year":"2022","journal-title":"Acta Biomed"},{"issue":"12","key":"10.1016\/j.jcf.2026.05.009_bib0028","article-title":"Potential use of GLP-1 and GIP\/GLP-1 receptor agonists for respiratory disorders: where are we at?","volume":"60","author":"Janic","year":"2024","journal-title":"Medicina (Kaunas)"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326001153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326001153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:41:55Z","timestamp":1779219715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326001153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":28,"alternative-id":["S1569199326001153"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.05.009","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in metabolic and pulmonary outcomes after discontinuation of glucagon-like-peptide-1 receptor agonist therapy in people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}